G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

NCT02983071 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Ductal, Breast
Breast Cancer
Breast Neoplasm

Interventions

DRUG: G1T38
DRUG: Fulvestrant

Sponsor

G1 Therapeutics, Inc.